PharmacyCodes



Allopurinolum [Inn-Latin] en es it fr

Categoria

Allopurinolum [Inn-Latin] Nombres de marca, Allopurinolum [Inn-Latin] Analogos

Allopurinolum [Inn-Latin] Marca los nombres de mezcla

  • No information avaliable

    • Allopurinolum [Inn-Latin] Formula quimica

    C5H4N4O

    Allopurinolum [Inn-Latin] RX enlace

    http://www.rxlist.com/cgi/generic/allopur.htm

    Allopurinolum [Inn-Latin] FDA hoja

    http://www.accessdata.fda.gov/scripts/cder/onctools/summary.cfm?ID=133

    Allopurinolum [Inn-Latin] MSDS (hoja de seguridad de materiales)

    Allopurinolum_[Inn-Latin] MSDS

    Allopurinolum [Inn-Latin] Sintesis de referencia

    Robins, J. Am. Chem. Por lo tanto. 78, 784 (1956)

    Allopurinolum [Inn-Latin] Peso molecular

    136.112 g/mol

    Allopurinolum [Inn-Latin] Punto de fusion

    350 oC

    Allopurinolum [Inn-Latin] H2O Solubilidad

    569 mg / L

    Allopurinolum [Inn-Latin] Estado

    Solid

    Allopurinolum [Inn-Latin] LogP

    -0.177

    Allopurinolum [Inn-Latin] Formas de dosificacion

    Comprimido para administración oral (100 mg, 200 mg y 300 mg), inyección

    Allopurinolum [Inn-Latin] Indicacion

    Para el tratamiento de la hiperuricemia asociados con la gota primaria o secundaria.

    Allopurinolum [Inn-Latin] Farmacologia

    El alopurinol, un análogo estructural de la base de purina naturales hipoxantina, se utiliza para prevenir la gota y los cálculos renales debido a el ácido úrico o de oxalato de calcio y para el tratamiento de la nefropatía por ácido úrico, hiperuricemia, y algunos tumores sólidos.

    Allopurinolum [Inn-Latin] Absorcion

    Aproximadamente el 90% es absorbido desde el tracto gastrointestinal.

    Allopurinolum [Inn-Latin] Toxicidad

    LD50 = 214 mg / kg (en ratones)

    Allopurinolum [Inn-Latin] Informacion de Pacientes

    Patients should be informed of the following:

    1. They should be cautioned to discontinue allopurinol and to consult their physician immediately at the first sign of a skin rash, painful urination, blood in the urine, irritation of the eyes, or swelling of the lips or mouth.
    2. They should be reminded to continue drug therapy prescribed for gouty attacks since optimal benefit of allopurinol may be delayed for two to six weeks.
    3. They should be encouraged to increase fluid intake during therapy to prevent renal stones.
    4. If a single dose of allopurinol is occasionally forgotten, there is no need to double the dose at the next scheduled time.
    5. There may be certain risks associated with the concomitant use of allopurinol and dicumarol, sulfinpyrazone, mercaptopurine, azathioprine, ampicillin, amoxicillin and thiazide diuretics, and they should follow the instructions of their physician.
    6. Due to the occasional occurrence of drowsiness, patients should take precautions when engaging in activities where alertness is mandatory.
    7. Patients may wish to take allopurinol after meals to minimize gastric irritation.

    Allopurinolum [Inn-Latin] Organismos afectados

    Humanos y otros mamíferos